China Money Network
Login
Join

China Biopharmaceutical Acquires Hegia for 1.2 Billion to Expand Small Nucleic Acid Capabilities

  • January 13, 2026 — 23:30 CST

This Data Is Locked!

This area is available only to Subscribers.

China Biopharmaceutical expands its portfolio with a 12 billion RMB acquisition of Hegia, a domestic siRNA innovative drug company. Hegia focuses on delivering siRNA innovative... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: